Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07354477 · ClinicalTrials.gov registry record · Phase 2
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
A Phase 2 study of Open Angle Glaucoma (OAG) and Non-proliferative Diabetic Retinopathy (NPDR), sponsored by Qlaris Bio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT07354477: Recruiting Phase 2 study of Open Angle Glaucoma (OAG) and Non-proliferative Diabetic Retinopathy (NPDR), sponsored by Qlaris Bio.
NCT07354477 is a Phase 2 study of Open Angle Glaucoma (OAG) and Non-proliferative Diabetic Retinopathy (NPDR) that is actively recruiting participants, run by Qlaris Bio. The registered enrollment target is 14 participants, below the 66-participant average among 5 other Open Angle Glaucoma (OAG) trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07354477, a Phase 2 study of Open Angle Glaucoma (OAG) and Non-proliferative Diabetic Retinopathy (NPDR), is actively recruiting participants, sponsored by Qlaris Bio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG
Primary Outcome
Ocular imaging will be collected at study visits at baseline, treatment period , and 1 week post-treatment and to evaluate change from baseline in retinal vessel diameter and blood flow.
Conditions Studied
Interventions
- DRUG QLS-111 Ophthalmic Solution (0.015%)
- DRUG QLS-111 Ophthalmic Solution (0.075%)
Study Locations (1)
California
- Stanford University, Dept. of Ophthalmology - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2026-02-20 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
What NCT07354477 shows while recruiting
NCT07354477 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 66-participant average among 5 other Open Angle Glaucoma (OAG) trials with a reported enrollment target (79% lower).
The record links to 3 conditions, with Open Angle Glaucoma (OAG) appearing as the primary indexed condition, and to 2 interventions - of which QLS-111 Ophthalmic Solution (0.015%) is the first listed.
NCT07354477 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07354477 about?
NCT07354477 is a clinical study titled "Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation". Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG
What is the current status of trial NCT07354477?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2026-02-20. Estimated completion is 2026-06.
What conditions does trial NCT07354477 study?
This clinical trial studies the following conditions: Open Angle Glaucoma (OAG), Non-proliferative Diabetic Retinopathy (NPDR), Normal Tension Glaucoma (NTG).
What interventions are being tested in trial NCT07354477?
The interventions under investigation include: QLS-111 Ophthalmic Solution (0.015%) (DRUG), QLS-111 Ophthalmic Solution (0.075%) (DRUG).
Who is sponsoring clinical trial NCT07354477?
This trial is sponsored by Qlaris Bio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07354477 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Open Angle Glaucoma (OAG)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Travoprost Five Day Posology Study
COMPLETED · Phase 2
-
DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma
RECRUITING
-
Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
RECRUITING
-
Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma
RECRUITING · NA
-
Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy